Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 15 - Sep 20
Accessibility and Convenience: Evaluate how easy it is to schedule consultations, access prescriptions, and communicate with medical professionals
Sensitivity analysis PP, repeated-measures and inverse probability weighting analyses were consistent with the primary outcome analysis (Supplementary Information)
[159] As of February 2026, Novo Nordisk has a market capitalization of $220.42 billion
Gastrointestinal adverse events Very common (10% or more): Diarrhea (35%), abdominal pain (21%), vomiting (21%), nausea (12%) Common (1% to 10%): Constipation, dyspepsia, gastrointestinal disorder, melena Very rare (less than 0.01%): Abdominal cramps [Ref] Nervous system Very common (10% or more): Headache (37%), dizziness (18%), paresthesia (12%) Common (1% to 10%): Hypertonia, vertigo, taste perversion Frequency not reported : Seizures (with or without pre-existing seizure activity), increase in seizure frequency and/or severity [Ref] Metabolic Very common (10% or more): Hypercalcemia (15%), hypervolemia (12%) Common (1% to 10%): Anorexia, hyperkalemia [Ref] There are reports from clinical trials of significant hypertriglyceridemia associated with high doses of levocarnitine (3 g/day) given to uremic dialysis patients
